结肠直肠癌的异质性

doi:10.16139/j.1007-9610.2018.05.001

摘要/Abstract

中图分类号:

蔡三军, 李清国. 结肠直肠癌的异质性[J]. 外科理论与实践, 2018, 23(05): 385-389.

[1] Grady WM, Carethers JM.Genomic and epigenetic instability in colorectal cancer pathogenesis[J]. Gastroentero-logy,2008,135(4):1079-1099.
[2] Laurent-Puig P, Agostini J, Maley K.Colorectal oncogenesis[J]. Bull Cancer,2010,97(11):1311-1321.
[3] Walther A, Houlston R, Tomlinson I.Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis[J]. Gut,2008,57(7):941-950.
[4] Juo YY, Johnston FM, Zhang DY, et al.Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis[J]. Ann Oncol,2014,25(12):2314-2327.
[5] Overman MJ, Lonardi S, Wong KYM, et al.Durable cli-nical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol,2018,36(8):773-779.
[6] Kopetz S, Mcdonough SL, Morris VK, et al.Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406)[J]. J Clin Oncol,2017,35(4 suppl):520.
[7] Cancer Genome Atlas N. Comprehensive molecular chara-cterization of human colon and rectal cancer[J]. Nature,2012,487(7407):330-337.
[8] Schlicker A, Beran G, Chresta CM, et al.Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines[J]. BMC Med Genomics,2012,5:66.
[9] Marisa L, de Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value[J]. PLoS Med,2013,10(5):e1001453.
[10] Sadanandam A, Lyssiotis CA, Homicsko K, et al.A colo-rectal cancer classification system that associates cellular phenotype and responses to therapy[J]. Nat Med,2013, 19(5):619-625.
[11] De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions[J]. Nat Med,2013,19(5):614-618.
[12] Budinska E, Popovici V, Tejpar S, et al.Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer[J]. J Pathol,2013,231(1):63-76.
[13] Roepman P, Schlicker A, Tabernero J, et al.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition[J]. Int J Cancer,2014,134(3):552-562.
[14] Muller MF, Ibrahim AE, Arends MJ.Molecular patholo-gical classification of colorectal cancer[J]. Virchows Arch,2016,469(2):125-134.
[15] Lee GH, Malietzis G, Askari A, et al.Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review[J]. Eur J Surg Oncol,2015,41(3):300-308.
[16] Price TJ, Beeke C, Ullah S, et al.Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?[J]. Cancer,2015,121(6):830-835.
[17] Cheng L, Eng C, Nieman LZ, et al.Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005[J]. Am J Clin Oncol,2011,34(6):573-580.
[18] Benedix F, Kube R, Meyer F, et al.Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histo-logy, and survival[J]. Dis Colon Rectum,2010,53(1):57-64.
[19] Meguid RA, Slidell MB, Wolfgang CL, et al.Is there a difference in survival between right- versus left-sided colon cancers?[J]. Ann Surg Oncol,2008,15(9):2388-2394.
[20] Snaebjornsson P, Jonasson L, Jonsson T, et al.Colon cancer in Iceland--a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age[J]. Int J Cancer,2010,127(11):2645-2653.
[21] Bettington M, Walker N, Clouston A, et al.The serrated pathway to colorectal carcinoma: current concepts and challenges[J]. Histopathology,2013,62(3):367-386.
[22] Fischer von Weikersthal L, Schalhorn A, Stauch M, et al. Phase Ⅲ trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer[J]. Eur J Cancer,2011,47(2):206-214.
[23] Venook A, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase Ⅲ trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)[J]. J Clin Oncol,2014,32(suppl 15):LBA 3.
[24] Weiss JM, Pfau PR, O′Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data[J]. J Clin Oncol,2011,29(33):4401-4409.
[25] Niida A, Nagayama S, Miyano S, et al.Understanding intratumor heterogeneity by combining genome analysis and mathematical modeling[J]. Cancer Sci,2018,109(4):884-892.
[26] Lee SY, Haq F, Kim D, et al.Comparative genomic analy-sis of primary and synchronous metastatic colorectal cancers[J]. PLoS One,2014,9(3):e90459.
[27] Knösel T, Schluns K, Stein U, et al.Chromosomal altera-tions during lymphatic and liver metastasis formation of colorectal cancer[J]. Neoplasia,2004,6(1):23-28.
[28] Luo D, Liu Q, Yu W, et al. Prognostic value of distant metastasis sites and surgery in stage Ⅳ colorectal cancer: a population-based study[J]. Int J Colorectal Dis,2018-06-21 [Epub ahead of print].
[29] Kim JH, Kang GH.Molecular and prognostic heterogenei-ty of microsatellite-unstable colorectal cancer[J]. World J Gastroenterol,2014,20(15):4230-4243.
[30] Yan Y, Lackner MR.FOXO3a and beta-catenin co-locali-zation: double trouble in colon cancer?[J]. Nat Med,2012,18(6):854-856.
[31] Ozawa T, Kandimalla R, Gao F, et al.A microRNA signature associated with metastasis of T1 colorectal cancers to lymph nodes[J]. Gastroenterology,2018,154(4):844-848.
[32] Li Y, Jia H, Yu W, et al.Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection[J]. Int J Cancer,2016,139(1):220-231.
[33] Li Y, Liang L, Dai W, et al.Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer[J]. Mol Cancer,2016,15(1):55.
[34] Li Q, Wu J, Wei P, et al.Overexpression of forkhead box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition[J]. Am J Cancer Res,2015,5(6):2022-2034.
[35] Li Q, Wei P, Huang B, et al.MAEL expression links epithelial-mesenchymal transition and stem cell properties in colorectal cancer[J]. Int J Cancer,2016,139(11):2502-2511.
[36] Li Q, Qin Y, Wei P, et al.Gas1 inhibits metastatic and metabolic phenotypes in colorectal carcinoma[J]. Mol Cancer Res,2016,14(9):830-840.
[37] Li Q, Wei P, Wu J, et al. The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhan-cing the Warburg effect[J]. Oncogene,2018-08-31.
[38] Adua D, Di Fabio F, Ercolani G, et al.Heterogeneity in the colorectal primary tumor and the synchronous resec-ted liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody[J]. Mol Clin Oncol,2017, 7(1):113-120.
[39] Touil Y, Igoudjil W, Corvaisier M, et al.Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis[J]. Clin Cancer Res,2014,20(4):837-846.
[40] Yang P, Yang Y, An W, et al.The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway[J]. J Gastroenterol Hepatol,2017,32(4):837-845.

结肠直肠癌的异质性

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	包全, 邢宝才. 复杂双叶多发性结肠直肠癌肝转移外科治疗策略[J]. 外科理论与实践, 2022, 27(02): 128-130.
[2]	刘诗光, 赵敬坤, 陆爱国, 毛志海. 趋化因子CXCL5和程序性死亡配体 1在结肠直肠癌组织的表达与病人预后的关系[J]. 外科理论与实践, 2021, 26(6): 543-549.
[3]	陈刚, 郑泽宇. 单细胞转录组学分析在胰岛β细胞生理研究中的应用进展[J]. 内科理论与实践, 2021, 16(06): 376-380.
[4]	张华, 陆炜, 杨承翌, 项明洁. 血清人衰老关键蛋白1检测对结肠直肠癌的诊断和预后价值[J]. 诊断学理论与实践, 2021, 20(05): 462-465.
[5]	杨盈赤, 宋建宁, 张忠涛. 中国腹腔镜结肠直肠手术的回顾与展望——基于手术病例登记研究和数据库建立的思考[J]. 外科理论与实践, 2021, 26(04): 277-280.
[6]	顾晋. 局部晚期结肠直肠癌治疗和联合脏器切除[J]. 外科理论与实践, 2021, 26(04): 290-296.
[7]	吴春晓, 龚杨明, 顾凯, 庞怡, 鲍萍萍, 王春芳, 施亮, 向詠梅, 窦剑明, 付晨, 施燕. 2016年上海市结肠直肠癌发病和死亡情况与2002—2016年间的变化趋势分析[J]. 外科理论与实践, 2021, 26(04): 325-335.
[8]	蔡三军. 结肠直肠癌诊治的思考[J]. 外科理论与实践, 2021, 26(04): 297-299.
[9]	张弢, 叶枫, 赵任. 结肠直肠癌的微创手术——在工具和价值间的不断平衡优化[J]. 外科理论与实践, 2021, 26(04): 300-304.
[10]	杨飖, 傅传刚. NOSES在结肠直肠癌手术中的应用现状与展望[J]. 外科理论与实践, 2021, 26(04): 305-311.
[11]	王常刚, 刘坤, 冯浩然, 蒋奕玫, 施毅卿, 陈献则, 宋子甲, 李军, 李佑, 蔡东莉, 赵任. 结肠直肠癌B7S1表达与免疫浸润的关系[J]. 外科理论与实践, 2021, 26(04): 336-342.
[12]	茅届齐, 徐多刚, 张米粒, 肖蕴誉, 明旭, 李雨哲, 曹灿, 于亮, 李继坤. 结肠直肠癌病人D-二聚体升高的研究[J]. 外科理论与实践, 2021, 26(04): 361-366.
[13]	张瑞, 苏敬博, 张健, 耿智敏. 胆道恶性肿瘤：从临床分型到分子分型[J]. 外科理论与实践, 2021, 26(02): 97-102.
[14]	程国柱, 蔡国响. 结肠直肠癌腹膜转移的腹腔药物治疗研究[J]. 外科理论与实践, 2021, 26(01): 34-37.
[15]	林松斌, 冯青阳, 许剑民. KRAS基因突变类型预测结肠直肠癌根治术后异时性远处转移[J]. 外科理论与实践, 2021, 26(01): 66-71.